Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?: A Clinical Perspective
- 1 March 2011
- journal article
- review article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 57 (9), 1053-1061
- https://doi.org/10.1016/j.jacc.2010.11.020
Abstract
No abstract availableFunding Information
- Actelion
- Gilead
- Lilly/Icos
- Pfizer
- Novartis
- United Therapeutics
- Actelion
- Bayer
- Gilead
- LungRx
- Pfizer
- United Therapeutics
- Actelion Pharmaceuticals
- Gilead Sciences
- United Therapeutics
- Pfizer
- Lung Rx
This publication has 45 references indexed in Scilit:
- Updated Clinical Classification of Pulmonary HypertensionJournal of the American College of Cardiology, 2009
- Development and Pathology of Pulmonary HypertensionJournal of the American College of Cardiology, 2009
- Diagnosis and Assessment of Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2009
- Cellular and Molecular Basis of Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2009
- Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2009
- Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary HypertensionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertensionEuropean Heart Journal, 2006
- Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2005
- Outcome in 91 Consecutive Patients with Pulmonary Arterial Hypertension Receiving EpoprostenolAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survivalJournal of the American College of Cardiology, 2002